CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Price, Forecast & Analysis
Canada - TSX:CRDL - CA14161Y2006 - Common Stock
CRDL.CA Key Statistics, Chart & Performance
The current stock price of CRDL.CA is 1.44 CAD. In the past month the price decreased by -0.69%. In the past year, price decreased by -43.31%.
CRDL.CA Latest News, Press Relases and Analysis
CRDL.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.65 | 3.26B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.71B | ||
| CRON.CA | CRONOS GROUP INC | 24.64 | 1.32B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.39 | 885.25M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 122.8 | 612.04M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.26 | 623.65M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 510.76M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 339.75M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 20.55 | 332.96M | ||
| HITI.CA | HIGH TIDE INC | N/A | 331.47M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 283.44M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 244.46M |
Related stock screener links
About CRDL.CA
Company Profile
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Company Info
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO L6H 0G5 CA
CEO: David G. Elsley
Employees: 18
Phone: 12899100850
CARDIOL THERAPEUTICS INC-A / CRDL.CA FAQ
What does CARDIOL THERAPEUTICS INC-A do?
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
What is the current price of CRDL stock?
The current stock price of CRDL.CA is 1.44 CAD. The price decreased by -2.04% in the last trading session.
What is the dividend status of CARDIOL THERAPEUTICS INC-A?
CRDL.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CRDL stock?
CRDL.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists CRDL stock?
CRDL.CA stock is listed on the Toronto Stock Exchange exchange.
What is the employee count for CRDL stock?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) currently has 18 employees.
What is the ownership structure of CARDIOL THERAPEUTICS INC-A (CRDL.CA)?
You can find the ownership structure of CARDIOL THERAPEUTICS INC-A (CRDL.CA) on the Ownership tab.
CRDL.CA Technical Analysis
CRDL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRDL.CA. CRDL.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CRDL.CA Financial Highlights
Over the last trailing twelve months CRDL.CA reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -188.33% | ||
| ROE | -318% | ||
| Debt/Equity | 0.01 |
CRDL.CA Forecast & Estimates
8 analysts have analysed CRDL.CA and the average price target is 9.95 CAD. This implies a price increase of 590.63% is expected in the next year compared to the current price of 1.44.